We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Seegene Reveals New Real-Time PCR at AACC 2014

By LabMedica International staff writers
Posted on 29 Jul 2014
Seegene Inc. More...
(Eschborn, Germany), a developer of multiplex PCR technologies, revealed their “MuDT” technology at the AACC 2014 meeting. MuDT is a real-time polymerase chain reaction (PCR) technology that will cause a shift in the PCR instrument market. The technology doubles the multiplexing capacity of any existing real-time PCR instrument––thus maximizing the value of the installed base of these instruments.

MuDT technology can be applied to any existing real-time PCR instrument and transforms it into a more powerful system by doubling its multiplexing capacity without upgrading the hardware.

The biotechnology industry has relied on real-time PCR for at least 20 years a molecular diagnostics technology, because of its versatility, speed, and ease of use. Despite many attempts, the biotechnology industry has not made significant advances that satisfy the growing demand for increased multiplexing and target quantification using limited numbers of channels in a single tube. Even melt curve analysis, after amplification has many disadvantages, such as end-point analysis after amplification, extended turnaround time, lack of quantification, and melt temperature variation due to target sequence variations on probe binding regions.

Additional benefits of the technology include: easier detection of multiple targets in a single channel without requiring melt curve analysis after amplification, SNP genotyping (homozygous wild type or mutant, or heterozygous) in a single channel.

Seegene is a global developer of multiplex molecular technologies and multiplex clinical molecular diagnostics that can simultaneously detect multiple targets with sensitivity, specificity, and reproducibility. The company's products detect multipathogens with good reliability and throughput, ultimately providing an economical basis for saving time, labor, and cost.

Related Links:

Seegene 



Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.